Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Earnings for Biofrontera Inc. (BFRI)
Earnings in 2024 (TTM): $-17,737,000
According to Biofrontera Inc.'s latest financial reports the company's current earnings (TTM) are $-17,737,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Biofrontera Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-17,737,000 | $-17,759,000 |
| 2023 | $-20,117,000 | $-20,131,000 |
| 2022 | $-608,000 | $-640,000 |
| 2021 | $-37,657,000 | $-37,713,000 |
| 2020 | $-10,923,000 | $-10,987,000 |
| 2019 | $-10,949,000 | $-10,982,000 |